Search Within

Paola Ghione

Formats
  1. Meeting Abstract (58)
  2. Journal Article (26)
  3. Editorial (3)
  4. Research Letter (3)
  5. Review (2)
Groups
  1. Sloan Kettering Institute Postdocs (92)
  2. Department of Medicine (78)
  3. Hematologic Malignancies, Division of (78)
  4. Center for Hematologic Malignancies (76)
  5. Lymphoma (75)
  6. Population Sciences Research Program (59)

More Groups

People
  1. Steven Horwitz (59)
  2. Alison Moskowitz (50)
  3. Maria Palomba (45)
  4. Ahmet Dogan (37)
  5. Ariela Noy (37)
  6. Andrew Zelenetz (35)

More People

Years
  1. 2025 (9)
  2. 2024 (29)
  3. 2023 (23)
  4. 2022 (2)
  5. 2021 (6)
  6. 2020 (14)

More Years

Publications
  1. Blood (45)
  2. Hematological Oncology (8)
  3. Journal of Clinical Oncology (6)
  4. Haematologica (5)
  5. Blood Advances (4)
  6. Leukemia and Lymphoma (3)

More Publications

Publishers
  1. American Society of Hematology (49)
  2. Wiley Blackwell (12)
  3. American Society of Clinical Oncology (6)
  4. Ferrata Storti Foundation (5)
  5. Taylor & Francis Group (4)
  6. Elsevier Inc. (3)

More Publishers

Results (92)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Reduced dose brentuximab vedotin for mycosis fungoides appears to prolong response duration by balancing efficacy and tolerability
    Meeting Abstract

    Munayirji, B.; Khan, N.; Myskowski, P.; Geller, S.; Noor, S.; Kheterpal, M. K.; Davey, T.; Hancock, H.; Perez, L.; Miller, T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Subcutaneous (SC) mosunetuzumab (mosun) as first-line therapy for patients (pts) with high tumor-burden follicular lymphoma (FL): First results of a multicenter phase 2 study
    Meeting Abstract

    Falchi, L.; Okwali, M.; Ghione, P.; Owens, C.; Hamlin, P. A.; Lue, J. K.; Epstein-Peterson, Z. D.; Palomba, M. L.; Kumar, A.; Torka, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Predicting toxicities in older adults with non-Hodgkin lymphoma (NHL) receiving systemic chemotherapy: A prospective geriatric assessment (GA) study
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-life experience with lenalidomide plus anti-CD20 antibodies for the treatment of patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL)
    Meeting Abstract

    Cassanello, G.; Rivas-Delgado, A.; Luna De Abia, A.; Corona, M.; Luttwak, E.; Okwali, M.; Isgor, I.; Galera, P.; Boardman, A. P.; Caron, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Association between geriatric impairments and quality of life in older adults with lymphoma on oral targeted therapies: A one‐year prospective study
    Meeting Abstract

    Torka, P.; Akhtar, O.; Kaijar, T.; Wang, K.; Attwood, K.; Carozza, D.; Bouchard, E.; Ghione, P.; Cortese, M.; Wildes, T.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • The prognostic value of progressing within 24 months of frontline chemoimmunotherapy (POD24) in relapsed/refractory (R/R) follicular lymphoma (FL)—a SCHOLAR‐5 analysis
    Meeting Abstract

    Patel, A. R.; Limbrick‐Oldfield, E. H.; Kanters, S.; Ray, M. D.; Best, T.; Ghione, P.; Neelapu, S. S.; Gribben, J. G.; Beygi, S.; Bobillo, S.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • BRCA1/2 mutations impact on the development of breast implant‐associated lymphoma (BIA‐ALCL) in women with breast cancer reconstructed with textured breast implants
    Meeting Abstract

    Ghione, P.; Arcila, M.; Joseph, V.; Dogan, A.; Cordeiro, P.; Salles, G.; de Jong, D.; Horwitz, S.; Mandelker, D.; van Leeuwen, F.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
    Journal Article

    Palomba, M. L.; Ghione, P.; Patel, A. R.; Nahas, M.; Beygi, S.; Hatswell, A. J.; Kanters, S.; Limbrick-Oldfield, E. H.; Wade, S. W.; Ray, M. D.; more...
    Expert Review of Anticancer Therapy (2023)

    Fulltext@MSK | Save